Biolexis Therapeutics, Inc.

United States - Salt Lake City, UT

• 30/11/2023
• Series A
• $10,000,000

Moleculern™ – The Next Evolution in Drug Discovery

Screening each Moleculern™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process.

Our empirically rich Moleculern™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.

Biolexis is developing better and safer drugs faster through Moleculern™:

Accelerates drug discovery/development to new therapeutics
Shortens the path to the clinic to increase the probability of success
Expedites to First-In-Human (FIH) clinical trials
Facilitates delivery of medicines to patients worldwide

Related People

David BearssCo Founder

United States - Lehi, Utah

"Good science is good medicine and good medicine is good business."
I am committed to developing meaningful medicines to improve and extend the lives of patients with serious diseases. I believe by targeting the molecular basis of diseases, we can leverage companion diagnostics or biomarkers to expand intellectual property, accelerate development, and improve patient outcomes.

I work to do more with less.
I challenge the status quo and don't just do things because that's what we've always done.
I trust and enable others to do their job.
I own the decisions for which I'm responsible.

LinkedIn https://www.linkedin.com/in/david-bearss-ph-d-072267/